

## IN THE CLAIMS

Claim 1 (previously presented). An abuse-proofed dosage form containing,

one or more active ingredients with abuse potential (A) selected from the group consisting of opiates and opioids,

optionally physiologically acceptable auxiliary substances (B),

at least one synthetic or natural polymer (C) comprising a polyalkylene oxide having a molecular weight of 1-15 million according to rheological measurements, and

optionally at least one wax (D),

said dosage form being a sintered mass and said component (C) being present in an amount sufficient to result in a breaking strength of said sintered mass of at least 500 N and wherein the active ingredient with abuse potential (A) is present in a controlled release matrix of component (C)..

Claim 2 (previously presented). The dosage form according to claim 1, which is in the form of a tablet.

Claim 3. Cancelled.

Claim 4 (previously presented). The dosage form according to Claim 1, wherein the polymer (C) is at least one polymer selected from the group consisting of polyethylene oxide, polymethylene oxide, polypropylene oxide, copolymers and the mixtures thereof.

Claim 5. Cancelled.

Claim 6        Cancelled.

Claim 7 (previously presented). The dosage form according to Claim 1, wherein the wax (D) is at least one natural, semi-synthetic or synthetic wax with a softening point of at least 60 °C.

Claim 8 (previously presented). The dosage form according to claim 7, wherein the wax (D) is carnauba wax or beeswax.

Claims 9 - 26.        Cancelled.

Claim 27 (**currently amended**). A process for the production of a dosage form according to claim 1, wherein components (A), the optionally present component (B), component (C) and the optionally present component (D) are mixed, and the resultant mixture, optionally after granulation, is press-formed with preceding, ~~or~~ simultaneous, or subsequent exposure to heat, to form a sintered mass.

Claim 28 (previously presented). The process according to claim 27, wherein granulation is performed by means of a melt process.

Claim 29 (previously presented). A dosage form obtained by the process of claim 27.

Claim 30.        Cancelled.

Claim 31 (previously presented). The dosage form according to claim 4, wherein polymer (C) is polyethylene oxide.

Claims 32-40. Cancelled.

Claim 41 (new). The dosage form according to claim 1, wherein the active ingredient with abuse potential (A) is oxycodone or a physiologically acceptable salt thereof.

Claim 42 (new). The dosage form according to claim 41, wherein component (C) is present in an amount of at least 73 wt.-%.